SYNTEKABIO, INC. 226330

KRX · South Korea · Technology Services

KRW 1,266.00-40.00 (-3.06%)

Market closed· Oct 2, 2026, 6:30 AM UTC· KRW · Data may be delayed

Company news

Yahoo FinanceFeb 04, 2026

MetaVia Announces Positive AI-Modeling Results from its Ongoing Syntekabio Collaboration, Confirming Key Therapeutic Targets for Vanoglipel

MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today provided an update on its ongoing collaboration with Syntekabio, Inc., an artificial intelligence (AI)-driven drug discovery company, leveraging their proprietary DeepMatcher® platform.

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.

Prices may be delayed and are for informational purposes only - not investment advice.